Total Payments
$115,031
2024 Payments
$35,480
Companies
16
Transactions
75
Medicare Patients
554
Medicare Billing
$258,149
Payment Breakdown by Category
Consulting$80,779 (70.2%)
Travel$22,940 (19.9%)
Other$6,924 (6.0%)
Food & Beverage$3,039 (2.6%)
Research$1,349 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $80,779 | 9 | 70.2% |
| Travel and Lodging | $22,940 | 17 | 19.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,285 | 4 | 5.5% |
| Food and Beverage | $3,039 | 34 | 2.6% |
| Unspecified | $1,349 | 10 | 1.2% |
| Compensation for serving as faculty or as a speaker for a medical education program | $638.70 | 1 | 0.6% |
Payments by Type
General
$113,682
65 transactions
Research
$1,349
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TransMedics, Inc. | $52,371 | 5 | $0 (2024) |
| United Therapeutics Corporation | $18,496 | 22 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $12,797 | 5 | $0 (2024) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $12,738 | 4 | $0 (2017) |
| Grifols Shared Services North America, Inc. | $4,608 | 6 | $0 (2019) |
| BOSTON SCIENTIFIC CORPORATION | $3,412 | 6 | $0 (2022) |
| Zambon USA Ltd. | $3,307 | 5 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $2,320 | 1 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,785 | 2 | $0 (2023) |
| SANOFI US SERVICES INC. | $1,349 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35,480 | 44 | United Therapeutics Corporation ($18,428) |
| 2023 | $55,031 | 8 | TransMedics, Inc. ($50,439) |
| 2022 | $6,193 | 6 | BOSTON SCIENTIFIC CORPORATION ($3,139) |
| 2021 | $144.01 | 1 | BOSTON SCIENTIFIC CORPORATION ($144.01) |
| 2020 | $347.56 | 1 | Boehringer Ingelheim Pharmaceuticals, Inc. ($347.56) |
| 2019 | $4,738 | 7 | Grifols Shared Services North America, Inc. ($4,608) |
| 2018 | $131.86 | 1 | Intuitive Surgical, Inc. ($131.86) |
| 2017 | $12,965 | 7 | Boehringer Ingelheim Pharma GmbH & Co.KG ($12,738) |
All Payment Transactions
75 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | Cash or cash equivalent | $75.00 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 11/15/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | Cash or cash equivalent | $34.41 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 11/14/2024 | XVIVO Perfusion Inc. | XVIVO Perfusion System (XPS) (Device) | Food and Beverage | In-kind items and services | $454.90 | General |
| Category: Transplantation | ||||||
| 11/13/2024 | United Therapeutics Corporation | — | Consulting Fee | Cash or cash equivalent | $7,840.00 | General |
| 11/13/2024 | United Therapeutics Corporation | — | Travel and Lodging | Cash or cash equivalent | $730.00 | General |
| 11/13/2024 | United Therapeutics Corporation | — | Travel and Lodging | Cash or cash equivalent | $653.82 | General |
| 11/13/2024 | United Therapeutics Corporation | — | Travel and Lodging | Cash or cash equivalent | $449.16 | General |
| 11/13/2024 | United Therapeutics Corporation | — | Travel and Lodging | Cash or cash equivalent | $349.37 | General |
| 11/13/2024 | United Therapeutics Corporation | — | Travel and Lodging | Cash or cash equivalent | $176.77 | General |
| 11/13/2024 | United Therapeutics Corporation | — | Food and Beverage | Cash or cash equivalent | $70.00 | General |
| 11/11/2024 | TransMedics, Inc. | Organ Care System (Device) | Travel and Lodging | Cash or cash equivalent | $1,126.54 | General |
| Category: Device | ||||||
| 10/29/2024 | TransMedics, Inc. | Organ Care System (Device) | Travel and Lodging | Cash or cash equivalent | $554.99 | General |
| Category: Device | ||||||
| 10/29/2024 | TransMedics, Inc. | Organ Care System (Device) | Travel and Lodging | Cash or cash equivalent | $250.91 | General |
| Category: Device | ||||||
| 10/29/2024 | United Therapeutics Corporation | Steen Solution (Device) | Food and Beverage | In-kind items and services | $79.74 | General |
| Category: Lung Transplant | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $299.93 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $272.70 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $254.40 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $84.40 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $74.87 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $27.23 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/26/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $27.23 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/25/2024 | SANOFI US SERVICES INC. | REZUROCK (Drug) | — | In-kind items and services | $198.74 | Research |
| Study: A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation • Category: Oncology | ||||||
| 10/08/2024 | Zambon USA Ltd. | — | Food and Beverage | In-kind items and services | $62.70 | General |
| 09/25/2024 | United Therapeutics Corporation | — | Food and Beverage | Cash or cash equivalent | $64.92 | General |
| 09/25/2024 | United Therapeutics Corporation | — | Food and Beverage | Cash or cash equivalent | $51.67 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A randomized, double-blind, placebo-controlled, parallel group, Phase 3 study, followed by an open-label extension, to evaluate the efficacy of oral belumosudil in adult participants with chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation | SANOFI US SERVICES INC. | $1,349 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 113 | 502 | $413,599 | $52,943 |
| 2022 | 3 | 122 | 609 | $553,249 | $74,456 |
| 2021 | 2 | 146 | 555 | $293,312 | $53,363 |
| 2020 | 3 | 173 | 774 | $547,911 | $77,387 |
Total Patients
554
Total Services
2,440
Medicare Billing
$258,149
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 51 | 281 | $170,848 | $24,183 | 14.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 17 | 105 | $174,195 | $17,334 | 10.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 45 | 116 | $68,556 | $11,426 | 16.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 27 | 229 | $345,332 | $39,327 | 11.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 47 | 243 | $134,379 | $19,578 | 14.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 48 | 137 | $73,538 | $15,552 | 21.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 83 | 268 | $139,193 | $30,505 | 21.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 63 | 287 | $154,119 | $22,858 | 14.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 75 | 365 | $190,165 | $29,830 | 15.7% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 22 | 151 | $227,708 | $26,263 | 11.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 76 | 258 | $130,038 | $21,294 | 16.4% |
About Dr. Marie Budev, DO
Dr. Marie Budev, DO is a Pulmonary Disease healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528022266.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marie Budev, DO has received a total of $115,031 in payments from pharmaceutical and medical device companies, with $35,480 received in 2024. These payments were reported across 75 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($80,779).
As a Medicare-enrolled provider, Budev has provided services to 554 Medicare beneficiaries, totaling 2,440 services with total Medicare billing of $258,149. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Cleveland, OH
- Active Since 04/12/2006
- Last Updated 01/28/2008
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1528022266
Products in Payments
- Organ Care System (Device) $52,371
- OFEV (Drug) $14,523
- Prolastin-C Liquid (Biological) $4,608
- General - Pulmonary (Device) $2,389
- CELLEX (Device) $2,320
- REZUROCK (Drug) $1,349
- General - Therapies (Device) $750.00
- XVIVO Perfusion System (XPS) (Device) $454.90
- Steen Solution (Device) $256.91
- GENERAL PULMONARY (Device) $144.01
- XERAVA (Drug) $143.77
- Da Vinci Surgical System (Device) $131.86
- GENERAL PULMONARY (Device) $129.11
- GIAPREZA (Drug) $128.36
- SherpaPak (Device) $122.31
- Cresemba (Drug) $117.14
- TYVASO (Drug) $43.51
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Cleveland
Neal Chaisson, Md, MD
Pulmonary Disease — Payments: $391,947
Pulmonary Disease $391,947
Michael Machuzak, M.d, M.D
Pulmonary Disease — Payments: $363,191
Pulmonary Disease $363,191
Dr. Joseph Cicenia, Md, MD
Pulmonary Disease — Payments: $244,813
Pulmonary Disease $244,813
Daniel Culver, Do, DO
Pulmonary Disease — Payments: $140,353
Pulmonary Disease $140,353
Dr. Tanmay Panchabhai, Md, MD
Pulmonary Disease — Payments: $124,047
Pulmonary Disease $124,047
James Stoller, M.d, M.D
Pulmonary Disease — Payments: $113,420
Pulmonary Disease $113,420